Thank you to all who joined us at the Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development conference to learn more about our research and the next generation of therapeutic development for neurodegenerative diseases.
Co-Founder and CEO, Damian Wheeler, presented a poster titled "Brain-Wide Cellular-Resolution Quantification of Microglia and Amyloid". At Translucence, we have optimized conditions for clearing brains and staining with antibodies to label both microglia and amyloid plaques. Our machine learning-enabled workflows label individual amyloid plaques throughout the brain. For microglia, we have developed two workflows. One labels cell bodies and is used for counting microglia. The other also labels processes to measure changes in shape associated with neuroinflammatory states.
Mapping individual brains to the Allen Brain Atlas allows for quantification of plaques and microglia across 100's of brain regions. Importantly, in 5xFAD Alzheimer's Disease model mice, activated microglia target amyloid plaques and become plaque-associated microglia (PAMs). We have developed workflows for brain-wide labeling and quantification of PAMs throughout the brain.
To learn more, please access our poster here.
Ask your question
Send us your questions and we will get back to you as soon as possible
info@translucencebio.com
